Trump Administration Reverses Course on Autism Drug Endorsement
The Trump administration has executed a significant policy reversal regarding a proposed autism treatment it had previously promoted with considerable enthusiasm. In September 2025, Health Secretary Robert F. Kennedy Jr. publicly championed leucovorin, a synthetic form of vitamin B9, labeling it an "exciting therapy" with potential to assist autistic children.
However, on Tuesday, March 10, 2026, the Food and Drug Administration officially backed away from this endorsement. The regulatory body cited a critical lack of sufficient evidence to support the drug's effectiveness in treating autism spectrum disorder.
Initial Promotion and Subsequent Reversal
The initial announcement came during a White House press conference where President Donald Trump and Secretary Kennedy presented leucovorin as a promising development for families affected by autism. "This gives hope to the many parents with autistic children that it may be possible to improve their lives," President Trump stated at the September event.
During that same conference, Trump offered controversial and unsubstantiated advice regarding autism prevention, including suggesting pregnant women should avoid Tylenol due to an unproven alleged link to autism—statements that were immediately criticized by the scientific community.
Kennedy, who has a long history of promoting debunked claims connecting vaccines to autism, specifically highlighted leucovorin's potential. The drug is conventionally used to mitigate side effects from chemotherapy but was being repositioned as an autism intervention.
FDA's Rationale and Scientific Context
The FDA clarified that while it is approving leucovorin for treatment of a rare condition known as cerebral folate deficiency, it explicitly is not endorsing its use for autism. "We don't have sufficient data to say that we could establish efficacy for autism more broadly," an unnamed FDA official explained to NBC News.
This decision follows concerns raised by dozens of autism specialists who warned in a joint letter that the administration's earlier promotion risked creating false hopes among vulnerable families. While some limited studies involving small patient groups have suggested leucovorin might help alleviate certain communication or interpersonal challenges associated with autism, experts universally agree that substantially more comprehensive research is necessary.
The FDA official further noted, "It'll be up to patients to talk with their physicians to see if that might be right for them," emphasizing the importance of individual medical consultation rather than broad administrative endorsement.
Broader Implications and Reactions
This reversal highlights ongoing tensions between political promotion of medical treatments and the rigorous evidence standards required by regulatory agencies. The administration's initial enthusiastic backing, followed by the FDA's evidence-based retraction, underscores the complexities of navigating hope, policy, and scientific validation in public health matters.
The episode also revisits controversies surrounding Kennedy's history with autism-related claims and the administration's approach to health communication. As research continues into autism spectrum disorder and potential interventions, this case serves as a reminder of the critical importance of robust clinical evidence before endorsing treatments for complex neurological conditions.
